Categories
Tags
Abbott Advertising AstraZeneca Barack Obama Biotechnology and Pharmaceuticals Breast cancer Bristol Myers Squibb business Cancer Clinical trial Conditions and Diseases Deal Eli Lilly European Commission European Union FDA Food and Drug Administration Genentech generics GlaxoSmithKline Google GSK HBA Health Health care Johnson & Johnson layoffs Lilly Margaret Hamburg Marketing Merck Novartis Pfizer Pharma Pharmaceutical drug pharmaceutical industry Research and development Roche Sanofi-Aventis Schering Plough social media Twitter U.S. Food and Drug Administration United States Wyeth
Technology News
BioPharm News- Shire Gains European Approval for its Gaucher Disease Treatment
- Mtech Bioprocess Scale-Up Facility to Double in Staff and Size
- ImClone Closes Plant in New Jersey, Consolidating Erbitux Manufacture
- EMA and FDA Seek Applicants for Joint GMP Inspections
- ATMI Expands Bloomington, Minnesota Manufacturing Facility
Clinical Trials News- CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems
- ACR Image Metrix Establishes Global Presence
- BioPharm Systems Named to the 2010 Inc. 500|5000 List of Fastest-Growing Companies in the U.S.
- CRF Health Doubles North American Headquarters
- Oracle Completes Acquisition of Phase Forward
Blogroll
-
Meta
Author Archives: Joanna Breitstein
Amid Big Pharma Woes, Shire in “Best Shape Everâ€
Angus Russell, Shire’s longtime CFO—now CEO—likens the failing US automobile industry to pharma. “All the problems with the automobile industry were a long time coming,†he says. “It’s just that the SUVs and the relatively cheap price of gas created a bubble, just like a booming economy and blockbusters.â€
But now that the bubble has burst, [...]
Posted in Deals, Emerging Markets, R&D, Strategy Tagged Angus Russell, Orphan Drugs, Shire 1 Comment
Conversation with Eisai’s Lonnel Coats
“The phones are ringing,†said Lonnel Coats, president of Eisai and a plenary speaker here at HBA’s Leadership Conference. “There’s a lot more opportunity, but also a lot more white noise.â€
Coats is referring to the pressure that cash-strapped biotechs are feeling to sell out and says he gets no less than five calls a day [...]
Posted in Events, Strategy Tagged Eisai, HBA, Lonnel Coats, M&A, MGI Pharma, venture capital Leave a comment
HBA Leadership Conference: Day 1
Reporting to you from Chicago at the Sixth Annual Healthcare Businesswomen’s Association leadership conference, where the story—set in this city of the new US President—is all about change.
The Pharm Exec crew arrived in a surprisingly tranquil Windy City—the only explanation that it was the calm after the storm of Tuesday’s election. Certainly, many HBA members [...]
Heat From FDAAA: Time For New GPP
Good Publication Practice, or GPP, is often the first port-of-call for companies publishing in the biomedical sector.
But consider this. The first ideas for GPP were formed a decade ago, and now the time is right for GPP2: the new, revised Good Publication Practice.
Why now? Pharma publication practice is a hot potato. Purported cases of publication-related [...]
Posted in Regulatory Tagged Chris Graf, clinicaltrials.gov, FDAAA, GPP, ICMJE, ISMPP, Publication Planning, Steering Committee Leave a comment

So Long and Thanks for the Memories